SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing strong momentum following rapid international approvals for Anktiva in the EU and Saudi Arabia, with the community actively anticipating a significant short squeeze fueled by high short interest and growing confidence in global revenue generation from Dr. Soon-Shiong's cancer-curing platform.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as community discussions highlight its critical role in powering AI data centers, underscored by its Meta partnership and anticipated DOE plutonium awards, while investors closely monitor its pre-revenue valuation and recent insider selling amidst a potential market bottom.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with sharply divided community sentiment, as bullish investors highlight new lending options on Coinbase and a reported COEP merger, while skeptics anticipate further declines for the meme coin amid ongoing speculation about Elon Musk's influence and X platform integration.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending amid recent news of an Aplix partnership leveraging its technology for e-money services, alongside its mainnet launch and institutional validation on Coinbase, sparking divided community opinion; while supporters emphasize long-term utility and regulatory progress, many others remain skeptical given persistent low price action and recent project setbacks.

SPDR Series Trust - State Street SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Growth ETF

SPYG is actively discussed as investors weigh an ongoing market rotation between growth and value, with the ETF's performance reflecting both recent pullbacks and strong rallies driven by key large-cap tech and AI names.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as the community eagerly anticipates a significant share repurchase program, reportedly up to EUR 1.5 billion, expected to be announced alongside its upcoming annual results. This potential capital return, combined with optimism surrounding its diversified aerospace, defense, and SMR nuclear energy initiatives, is driving strong bullish sentiment.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending at new highs, primarily driven by robust demand for AI chips and infrastructure, as validated by strong earnings and positive guidance from key component companies. While this sustained growth fuels strong bullish sentiment, it also sparks an intense community debate regarding the sector's "parabolic" run and potential overvaluation, with some pointing to cooling GPU rental rates as a cautionary sign.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending following strong quarterly earnings and an optimistic outlook, confirming robust demand for AI chips and the company's significant capital expenditure plans to expand advanced manufacturing capacity. The community highlights its crucial role as the backbone of the global AI supply chain, alongside discussions of its US expansion and geopolitical considerations, with many noting its continued market dominance.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly awaits its imminent BLA resubmission for deramiocel, with high expectations for a significant rally and potential buyout given its "life-saving" potential for Duchenne Muscular Dystrophy patients. Further discussions highlight optimism for accelerated approval, especially amidst evolving FDA policies and widespread calls for regulatory clarity in the rare disease space.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is trending as an activist investor's formal proxy contest against current management fuels intense debate over the company's strategy to address substantial debt by divesting Del Taco at a significant loss. Community discussion is sharply divided between concerns over financial health and the potential for a short squeeze driven by high bearish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exagen (NASDAQ:XGN) Price Target Lowered to $10.00 at BTIG Research

BTIG Research reduced their price target on Exagen from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday...

Exagen Inc. (NASDAQ:XGN) Short Interest Down 67.3% in January

Exagen Inc. (NASDAQ:XGN - Get Free Report) saw a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 586,232 shares, a decrease of...

Exagen Inc. (NASDAQ:XGN) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Exagen Inc. (NASDAQ:XGN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat reports. One analyst has...

Short Interest in Exagen Inc. (NASDAQ:XGN) Expands By 65.7%

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,793,289...

Exagen's (XGN) "Buy" Rating Reaffirmed at B. Riley

B. Riley restated a "buy" rating and issued a $8.00 price objective (down previously from $18.00) on shares of Exagen in a research note on Friday...

Exagen Inc. (NASDAQ:XGN) Sees Large Growth in Short Interest

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,082,304...

Exagen Inc. (NASDAQ:XGN) Given Consensus Rating of "Moderate Buy" by Brokerages

Exagen Inc. (NASDAQ:XGN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the firm, Marketbeat reports. One investment...

67,600 Shares in Exagen Inc. $XGN Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI purchased a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The...

75,413 Shares in Exagen Inc. $XGN Acquired by Calamos Advisors LLC

Calamos Advisors LLC acquired a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities...

BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock

BTIG Research increased their price objective on Exagen from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Monday...

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Current Price	$3.41
Prev Close	$3.27
Open	$3.24
Dividend Yield	0.00%
50-Day Moving Average	$5.09
Beta	1.08
Avg. Volume	681,246.55
PE Ratio	-3.68

52-Week High	$12.23
52-Week Low	$2.67
Market Capitalization	$77.28M
EPS (Annual)	-$0.8304
Price to Book	4.23
Revenue Per Employee	$266,224.88

XGN
Exagen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XGN News

XGNExagen Inc